OakChart

Milestone Scientific Inc

MLSSHealthcare·Medical Instruments & Supplies·USA·Nano·AMEX·Nov 11 • 9:31 AM ET

0.3059+0.0140 (4.80%)
2026-11-11 15:31 CET
Market cap
26.46 USD m
Revenue, TTM
9.42 USD m
Net income, TTM
-4.14 USD m
Free cash flow, TTM
-0.66 USD m
EPS diluted, TTM
-0.05
P/E
-
Compare

Price

MLSS against its 20, 50 and 200-day averages
2050200beatearnings
0.300.400.50436K871KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MLSSclose 0.3120-day 0.3150-day 0.37200-day 0.350.31

47.2% under 0.58 on 13 Aug 2026. Last 15 sessions, 22.8% high to low

Profile

MLSS
52-week range, 24% of the way up
0.220.58

Milestone Scientific, Inc. is a biomedical technology research and development company, which patents, designs, and develops diagnostic and therapeutic injection technologies and instruments. It operates through the following segments: Dental, Medical, and Corporate. The Corporate segment refers to executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities, and public company compliance costs. Its solutions include CompuFlo Epidural, CathCheck Verification System, and Single Tooth Anesthesia System. The company was founded on August 17, 1989 and is headquartered in Roseland, NJ.

Employees15
IPONov 03, 1995
Beta1.16
ATR, 14d0.03
Rel volume0.39
Short float0.10%
Insider own16.08%
Inst own5.28%

Snapshot

6 groups

Valuation

Index-
Market Cap27.73M
Enterprise Value26.28M
Income-4.14M
Sales9.42M
Book/sh0.04
Cash/sh0.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPONov 03, 1995

Ratios

P/E-
Forward P/E-
PEG-
P/S2.94
P/B7.82
P/C13.40
P/FCF-
EV/EBITDA-
EV/Sales2.79
Quick Ratio1.14
Current Ratio1.85
Debt/Eq0.18
LT Debt/Eq0.14
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.05
EPS next Y-0.04
EPS next Q-0.01
EPS this Y42.86%
EPS next Y12.50%
EPS next 5Y34.14%
EPS past 3/5Y17.32% 9.75%
Sales past 3/5Y0.63% 10.54%
EPS Y/Y TTM43.78%
Sales Y/Y TTM3.72%
EPS Q/Q37.02%
Sales Q/Q22.28%
EarningsAug 14 BMO
EPS/Sales Surpr.0.00% 5.22%

Ownership

Insider Own16.08%
Insider Trans0.00%
Inst Own5.28%
Inst Trans0.38%
ROA-50.54%
ROE-121.67%
ROIC-104.89%
Gross Margin69.40%
Oper. Margin-43.56%
Profit Margin-43.98%
SMA20-2.05%
SMA50-16.46%
SMA200-13.82%
Trades-

Technical

Shs Outstand88.76M
Shs Float76.07M
Short Float0.10%
Short Ratio0.68
Short Interest0.08M
52W High0.58 -47.22%
52W Low0.22 40.26%
Volatility10.09% 9.85%
ATR (14)0.03
RSI (14)42.40
Beta1.16
Rel Volume0.39
Avg Volume116.17K
Volume2,375

Performance

Perf Week-7.02%
Perf Month-10.03%
Perf Quarter-44.68%
Perf Half Y-12.70%
Perf YTD12.05%
Perf Year-17.55%
Perf 3Y-59.75%
Perf 5Y-87.15%
Perf 10Y-83.01%
Recom1.00
Target Price1.25
Prev Close0.29
Price0.31
Change %4.80%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Sep 16, 2020InitiatedNNorthland CapitalMarket Perform
Nov 16, 2018ReiteratedMMaxim GroupBuy$3 → $1.50+390.4%
Dec 23, 2016ReiteratedMMaxim GroupBuy$5 → $4+1,207.6%
Dec 11, 2015InitiatedMMaxim GroupBuy$5+1,534.5%

Peers

Mkt cap
TickerCompanyMkt cap
PDEXPro-Dex Inc227.17M
KRMDKORU Medical Systems Inc155.37M
XRAYDENTSPLY Sirona Inc1.89B
NVSTEnvista Holdings Corp4.16B
UTMDUtah Medical Products Inc207.12M
ICUIICU Medical Inc4.20B
BDXBecton Dickinson & Co57.54B
VVOSVivos Therapeutics Inc3.02M
PCRXPacira BioSciences Inc1.46B
HSICHenry Schein Inc9.80B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 202
  • Milestone Scientific Provides Major Commercial Growth Update as CompuFlo Expands Across 30 Million+ Annual Global Epidural Procedures (GlobeNewswire)
  • Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo Medical Business (GlobeNewswire)
  • Milestone Scientific Announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo Development Partner and Advisor (GlobeNewswire)
  • Milestone Scientific Achieves Debt-Free Balance Sheet Through Debt-to-Equity Conversion by Three Directors (GlobeNewswire) +11.22%
  • Milestone Scientific Inc (MLSS) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% on ... (GuruFocus.com) -10.47%
  • Loading…
  • Milestone Scientific Reports Financial Results for Second Quarter 2026 (GlobeNewswire)
  • Earnings To Watch: Milestone Scientific Inc (MLSS) Q2 2026 -- GF Value Sees 13% Upside (GuruFocus.com)
  • Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call (GlobeNewswire)
  • Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo Epidural System (GlobeNewswire)
  • Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026 (GlobeNewswire) +5.33%
  • Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY (GlobeNewswire) +9.19%
  • Milestone Scientific Strengthens Board to Support Next Phase of Growth (GlobeNewswire)
  • Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo Across Epidural, Neuromodulation, and Interventional Pain Procedures (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.010-0.010-0.0102.842.702
2026Q12026-05-13-0.010-0.015-0.0102.162.252
2025Q42026-03-31-0.020-0.015-0.0142.062.312
2025Q32025-11-13-0.010-0.015-0.0142.362.252
2025Q22025-08-14-0.020-0.010-0.0182.322.601
2025Q12025-05-15-0.020-0.010-0.0242.232.501
2024Q42025-04-15-0.020-0.010-0.0262.012.701
2024Q32024-11-15-0.020-0.010-0.0182.512.612
2024Q22024-08-150.000-0.0100.0031.852.521
2024Q12024-05-16-0.020-0.020-0.0182.252.421
2023Q42024-04-01-0.030-0.020-0.0262.262.421
2023Q32023-11-15-0.020-0.020-0.0202.062.761
2023Q22023-08-15-0.030-0.020-0.0312.912.671
2023Q12023-05-11-0.020-0.030-0.0182.602.121
2022Q42023-03-31-0.020-0.030-0.0292.242.521
2022Q32022-11-15-0.030-0.030-0.0282.222.091

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-0.160-0.170-0.16011.2811.07
2018FY-0.210-0.260-0.2119.627.90
2019FY-0.160-0.160-0.1658.388.38
2020FY-0.120-0.135-0.1165.445.23
2021FY-0.100-0.110-0.09910.309.86
2022FY-0.120-0.130-0.1238.819.08
2023FY-0.100-0.090-0.0959.839.99
2024FY-0.060-0.050-0.0598.639.30
2025FY-0.070-0.070-0.0708.979.22
2026FY--0.040--9.97
2027FY--0.035--11.35
2028FY--0.020--14.04

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-282002.412.322.50
2026Q3S2026-08-172012.412.322.50
2026Q3S2026-08-142012.412.312.50
2026Q3S2026-07-012002.512.502.52
2026Q3S2026-06-112002.512.502.52
2026Q3S2026-06-092012.512.502.52
2026Q3S2026-05-142112.512.502.52
2026Q3S2026-04-012112.502.502.50
2026Q3S2026-02-022002.502.402.60
2026Q3S2026-01-312012.502.402.60
2026Q3S2025-11-192112.502.402.60
2026Q3S2025-11-172102.652.402.90
2026Q3S2025-11-142002.632.372.90
2026Q3S2025-11-112002.632.372.90

Estimate history

EPS, annual-0.16-0.211-0.165-0.116-0.099-0.123-0.095-0.059-0.07-0.0488
Period201720182019202020212022202320242025TTM
EPS, quarterly0.003-0.018-0.026-0.024-0.018-0.014-0.014-0.01-0.011
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual11.2829.6228.3755.43710.3058.8069.8278.638.9749.42
Period201720182019202020212022202320242025TTM
Sales, quarterly1.8542.5142.0142.2322.3232.362.0582.1622.841
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual33.15833.82649.37764.13868.1269.27375.84978.01480.45388.757
Period201720182019202020212022202320242025MRQ
Shares, quarterly77.19477.67678.01478.19778.55978.55980.45380.45388.757
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue9.428.978.639.838.8110.305.448.379.62
Cost of Goods Sold Incl. D&A2.882.642.233.103.974.071.822.665.19
Gross Profit6.546.336.406.734.846.243.625.724.43
Selling, General and Administrative Excl. Other10.6412.0313.1513.8413.6613.6211.079.7210.89
Research and Development0.040.450.860.701.150.880.310.190.25
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-4.10-5.70-6.76-7.11-8.83-7.38-7.45-4.00-6.46
Interest Expense-0.03---0.02-0.000.00
Unusual Expense0.000.000.000.000.00-0.280.003.641.54
Net Income Before Taxes-4.14-5.72-4.71-6.98-8.77-7.12-7.47-7.64-8.00
Income Taxes0.000.000.000.000.000.000.020.020.02
Consolidated Net Income-4.14-5.72-4.71-6.98-8.77-6.88-7.39-7.58-7.69
Net Income From Continuing Operations-4.14-5.72-4.71-6.93-8.71-6.82-7.34-7.52-7.43
Net Income-4.14-5.72-4.71-6.93-8.71-6.82-7.34-7.52-7.43
EPS (Recurring)-0.04-0.07-0.06-0.10-0.12-0.10-0.12-0.11-0.18
EPS (Basic, Before Extraordinaries)-0.05-0.07-0.06-0.10-0.12-0.10-0.12-0.16-0.21
EPS (Diluted)-0.05-0.07-0.06-0.10-0.12-0.10-0.12-0.16-0.21
EBITDA-3.92-5.51-6.62-6.96-8.68-7.25-7.32-3.74-5.58
Non-Operating Income (Expense)0.000.002.040.130.050.00-0.02-0.010.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.970.951.351.471.500.580.400.130.32
Price To Sales Ratio3.172.508.885.113.8513.7624.597.591.22
Gross Margin69.4070.5374.1368.4954.9360.5466.6068.2846.05
Operating Margin-43.56-63.48-78.30-72.31-100.24-71.60-137.08-47.75-67.13
Net Margin-43.98-63.76-54.62-70.51-98.87-66.17-134.94-89.85-77.24
Shares Outstanding88.7680.4578.0175.8569.2768.1264.1449.3833.83
Market Capitalization26.4626.4674.7852.1733.50139.76135.0367.9511.22

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue2.842.162.062.362.322.232.012.51
Cost of Goods Sold Incl. D&A0.950.620.580.740.730.600.510.69
Gross Profit1.891.541.481.621.601.631.501.83
Selling, General and Administrative Excl. Other2.952.372.562.763.083.633.543.30
Research and Development0.010.000.010.020.050.370.220.23
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.06-0.83-1.08-1.13-1.48-2.00-2.04-1.47
Interest Expense-0.010.010.02----
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-1.06-0.84-1.09-1.15-1.48-1.99-2.04-1.46
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.06-0.84-1.09-1.15-1.48-1.99-2.04-1.46
Net Income From Continuing Operations-1.06-0.84-1.09-1.15-1.48-1.99-2.04-1.46
Net Income-1.06-0.84-1.09-1.15-1.48-1.99-2.04-1.46
EPS (Recurring)-0.01-0.01-0.01-0.01-0.02-0.02-0.03-0.02
EPS (Basic, Before Extraordinaries)-0.01-0.01-0.01-0.01-0.02-0.02-0.03-0.02
EPS (Diluted)-0.01-0.01-0.01-0.01-0.02-0.02-0.03-0.02
EBITDA-1.01-0.78-1.03-1.10-1.43-1.95-2.01-1.44
Non-Operating Income (Expense)0.000.000.000.000.000.000.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.250.260.100.360.160.330.340.48
Price To Sales Ratio3.172.752.454.195.758.868.688.20
Gross Margin66.5571.4472.0468.6768.7872.9374.6172.70
Operating Margin-37.37-38.30-52.46-48.07-63.90-89.49-101.43-58.44
Net Margin-37.29-38.85-52.99-48.89-63.83-89.35-101.09-58.13
Shares Outstanding88.7680.4580.4578.5678.5678.2078.0177.68
Market Capitalization26.4622.6521.4735.6949.9572.6474.7870.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1.113.265.958.7214.7614.221.520.742.64
Short Term Receivables2.111.751.682.022.251.492.422.734.46
Inventories3.783.712.641.791.542.421.621.923.38
Other Current Assets0.470.560.520.440.380.420.540.410.44
Total Current Assets7.489.2910.7912.9718.9318.556.095.8110.91
Net Property, Plant & Equipment0.230.340.370.480.570.660.040.080.14
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable-------0.000.65
Intangible Assets0.080.150.180.230.280.330.380.442.79
Other Assets0.020.020.020.020.020.020.040.081.14
Total Assets7.819.8011.3713.7019.8119.576.566.4015.63
Short Term Debt Incl. Current Port. of LT Debt0.160.130.110.100.090.360.020.000.00
Accounts Payable2.791.511.101.911.180.872.742.871.96
Other Current Liabilities1.182.101.861.291.831.652.172.004.76
Total Current Liabilities4.133.743.083.303.102.884.934.876.73
Long Term Debt0.860.220.280.400.500.590.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.001.40
Total Liabilities4.993.963.363.703.593.464.934.878.13
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.007E-067E-06
Common Equity2.815.838.0110.2316.3716.201.701.547.24
Total Shareholders Equity2.815.838.0110.2316.3716.201.701.547.24
Accumulated Minority Interest0.000.000.00-0.22-0.15-0.09-0.07-0.010.26
Total Equity2.815.838.0110.0116.2216.111.631.537.50
Total Liabilities & Stockholders Equity7.819.8011.3713.7019.8119.576.566.4015.63
Book Value Per Share0.030.070.110.150.240.250.030.050.22
Tangible Book Value Per Share0.030.070.100.140.240.250.030.030.13
Full-Time Employees151717202619161614
Price to Book Ratio7.4610.336.752.908.578.3940.477.284.43
Return on Assets-65.01-44.53-55.27-51.96-34.63-56.16-116.14-67.47-35.55
Return on Equity-132.38-68.09-75.98-65.48-41.87-81.99-465.11-169.22-65.89
Return on Invested Capital-155.70-77.87-83.54-81.97-40.43-43.71-443.67-482.70-71.60
Quick Ratio0.891.492.653.395.625.610.910.801.12
Current Ratio1.812.483.513.936.116.451.241.191.62

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-4.14-5.72-4.71-6.98-8.77-6.88-7.39-7.58-7.69
Depreciation0.190.190.130.150.140.020.130.260.88
Other Funds (Non Cash)2.462.712.292.903.151.772.093.743.41
Funds from Operations-1.49-2.82-2.29-3.93-5.48-5.08-5.17-3.59-3.40
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.85-0.09-0.63-1.40-0.551.07-1.811.811.77
Cash from Operating Activities-0.64-2.92-2.92-5.33-6.03-4.02-6.98-1.78-1.63
Capital Expenditures-0.02-0.02-0.01-0.00-0.01-0.02-0.02-0.01-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-0.01
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.002.98-2.970.000.000.000.000.00
Purchase of Investments0.000.000.00-7.930.000.000.000.00-
Sale Or Maturity of Investments0.000.002.984.970.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.022.97-2.97-0.01-0.02-0.02-0.01-0.02
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.470.000.242.570.004.6019.452.560.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.470.000.242.570.004.6019.452.560.00
Proceedsfrom Stock Options1.470.000.192.570.000.0018.042.220.00
Issuance or Reduction of Debt, Net-0.010.79-0.01-0.01-0.01-0.020.270.000.00
Change in Long Term Debt-0.010.79-0.01-0.01-0.01-0.02-0.010.000.00
Issuance of Long Term Debt0.000.800.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.01-0.01-0.01-0.01-0.02-0.010.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00-0.25
Other Financing Activities Uses0.000.000.000.000.000.000.000.00-0.25
Cash from Financing Activities1.450.790.232.56-0.014.5719.712.56-0.25
Net Change in Cash0.79-2.150.28-5.74-6.050.5412.710.77-1.89
Free Cash Flow-0.66-2.93-2.93-5.33-6.04-4.03-7.01-1.79-1.64
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments2.071.191.111.351.272.25
Short Term Receivables2.331.992.112.131.821.47
Inventories3.093.493.784.133.904.16
Other Current Assets0.630.680.470.510.640.75
Total Current Assets8.127.357.488.117.638.62
Net Property, Plant & Equipment0.160.190.230.260.280.31
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.040.060.080.100.110.13
Other Assets0.020.360.020.020.020.02
Total Assets8.357.967.818.498.059.09
Short Term Debt Incl. Current Port. of LT Debt0.140.160.160.150.140.14
Accounts Payable2.863.262.793.041.962.68
Other Current Liabilities1.401.431.181.841.671.63
Total Current Liabilities4.404.864.135.033.774.44
Long Term Debt0.480.820.860.900.940.18
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.885.684.995.944.714.63
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.472.282.812.553.344.46
Total Shareholders Equity3.472.282.812.553.344.46
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.472.282.812.553.344.46
Total Liabilities & Stockholders Equity8.357.967.818.498.059.09
Book Value Per Share0.040.030.030.030.040.06
Tangible Book Value Per Share0.040.030.030.030.040.06
Full-Time Employees--15---
Price to Book Ratio7.4610.148.4110.6811.1510.03
Return on Assets-50.54-53.57-65.01-67.82-69.55-51.55
Return on Equity-121.67-135.39-132.38-136.47-123.50-88.36
Return on Invested Capital-26.81-27.04-29.67-33.42-34.63-42.95
Quick Ratio1.140.790.890.790.991.00
Current Ratio1.851.511.811.612.031.94

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.06-0.84-1.09-1.15-1.48-1.99
Depreciation0.050.050.050.040.050.05
Other Funds (Non Cash)0.430.321.360.360.370.62
Funds from Operations-0.58-0.480.32-0.75-1.06-1.32
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.000.56-0.540.83-0.700.32
Cash from Operating Activities-0.590.09-0.230.08-1.76-1.01
Capital Expenditures-0.00-0.00-0.00-0.01-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.00-0.00-0.01-0.00-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.470.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.470.000.000.000.000.00
Proceedsfrom Stock Options1.470.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.00-0.00-0.00-0.000.80-0.00
Change in Long Term Debt-0.00-0.00-0.00-0.000.80-0.00
Issuance of Long Term Debt0.000.000.000.000.800.00
Reduction of Long Term Debt-0.00-0.00-0.00-0.00-0.00-0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.46-0.00-0.00-0.000.80-0.00
Net Change in Cash0.870.08-0.230.07-0.97-1.01
Free Cash Flow-0.590.09-0.230.08-1.77-1.01

Revenue breakdown

Handpieces2024: 6.97M 2025: 7.14M
Instruments2024: 1.57M 2025: 1.76M
Other2024: 90.12K 2025: 74.76K
China2025: 310.00K
Rest of World2024: 3.38M 2025: 3.69M
United States2024: 5.25M 2025: 4.97M
Dental2024: 8.53M 2025: 8.79M
Medical2024: 104.62K 2025: 183.25K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.10%0.1M76.1M123.63K
2026-10-150.11%0.1M76.1M125.11K
2026-09-300.11%0.1M75.8M127.75K
2026-09-150.12%0.1M75.8M159.75K
2026-08-310.11%0.1M74.2M173.27K
2026-08-140.28%0.2M74.1M192.41K
2026-07-310.15%0.1M73.9M269.01K
2026-07-150.23%0.2M73.9M495.51K
2026-06-300.36%0.3M73.8M2.11M
2026-06-150.28%0.2M74.5M2.08M
2026-05-290.73%0.5M72.9M2.10M
2026-05-151.55%1.1M69.0M2.08M
2026-04-304.05%2.5M62.6M2.02M
2026-04-151.13%0.6M51.9M1.86M
2026-03-310.16%0.1M51.9M221.69K
2026-03-130.25%0.1M50.8M293.65K
2026-02-270.33%0.2M50.8M330.56K
2026-02-130.55%0.3M50.8M763.81K
2026-01-300.59%0.3M50.8M1.31M
2026-01-150.77%0.4M50.8M1.27M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.000.03-1.000.00---
call5.000.000.000.00-0.000.00---
call7.500.000.000.00-0.000.00---
put2.500.000.002.25-22.000.00---
put5.000.000.004.75-8.000.00---
put7.500.000.007.25-5.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-28EFFECTEffectiveness filing by commission orderSEC
2026-09-18S-3/ASEC
2026-09-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-08S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-318-KCurrent report2026-07-27SEC
2026-07-298-KCurrent report2026-07-24SEC
2026-06-258-KCurrent report2026-04-30SEC
2026-06-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-22SEC
2026-06-10PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-09EFFECTEffectiveness filing by commission orderSEC
2026-06-09424B1SEC
2026-06-08CORRESPSEC
2026-06-08UPLOADUpload SubmissionSEC
2026-06-05PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-05SEC
2026-06-02S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-04-30SEC
2026-05-068-KCurrent report2026-04-30SEC
2026-05-0510-K/A2025-12-31SEC
2026-04-23DNotice of sales of securities on Form D (Regulation D)SEC
2026-04-218-KCurrent report2026-04-20SEC
2026-04-028-KCurrent report2026-03-31SEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-118-KCurrent report2026-03-10SEC
2026-02-048-K/A2026-01-15SEC
2026-01-208-KCurrent report2026-01-15SEC
2025-12-238-KCurrent report2025-12-18SEC
2025-11-138-KCurrent report2025-11-07SEC
2025-11-1310-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.34%
GEODE CAPITAL MANAGEMENT, LLC0.72%
VANGUARD FIDUCIARY TRUST CO0.53%
STATE STREET CORP0.30%
NFSG Corp0.24%
NORTHERN TRUST CORP0.15%
LPL Financial LLC0.14%
Mariner, LLC0.14%
World Investment Advisors0.12%
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.11%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.64%
VANGUARD EXTENDED MARKET INDEX FUND0.69%
Fidelity Extended Market Index Fund0.41%
Fidelity Total Market Index Fund0.11%
Ultra-Small Company Market Fund0.11%
Fidelity Series Total Market Index Fund0.09%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.01%

OakChart. MLSS. Cached 15 minutes.

Some panels did not load: insider.